Key result
Elevated Lp(a) causes severe premature CAD in low-risk female, underscoring need for universal screening.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
This case highlights the clinical importance of universally screening for elevated Lipoprotein(a) to prevent the underestimation of cardiovascular risk in patients who otherwise appear to be at low risk.
Introduction: Atherosclerosis cardiovascular disease (ASCVD), especially coronary artery disease (CAD), remains the leading cause of death worldwide, with several well-identified risk factors. This case report presents a premenopausal female with low calculated ASCVD risk, hypertension, elevated lipoprotein(a) [Lp(a)], and clinically significant CAD. Case report: A 44-year-old premenopausal White female with controlled stage 2 hypertension, and overall low calculated 10-year ASCVD risk, was found to have severe CAD. She presented to the clinic with worsening chest discomfort during exertion and was diagnosed with a heavily calcified proximal left anterior descending artery stenosis, necessitating percutaneous coronary intervention. Discussion: The global prevalence of elevated Lp(a) >50 mg/dL is around 1.43 billion. Elevated lipoprotein(a) is now recognized, based on the preponderance of the evidence, by several international scientific statements as an independent risk factor for ASCVD, including CAD. Nevertheless, the current 2018 American College of Cardiology (ACC) and American Heart Association (AHA) multi-society guideline on the Management of Blood Cholesterol only classifies Lp(a) as a risk enhancer. This recommendation, along with the lack of approved pharmacotherapy has contributed to limited testing in current United States clinical practice (<1 % for the general population). Furthermore, the inadequate assessment of Lp(a) may lead to an underestimation of ASCVD risk. Conclusion: This case highlights the shortcomings of inadequate assessment of Lp(a) leading to the underestimation of cardiovascular risk. Accordingly, with multiple recent international scientific statements, clinicians should universally screen for elevated Lp(a). In the future, investigational therapies for lowering Lp(a) may be crucial for improving patient outcomes.
No takes yet. Share an insight, caveat, or question.
Villavaso et al. (2025) conducted a case report in Coronary artery disease (n=1). Elevated lipoprotein(a) was evaluated on Severe coronary artery disease. Elevated lipoprotein(a) was identified as the cause of severe coronary artery disease in a 44-year-old female with low ASCVD risk, highlighting the need for universal screening.
Synapse has enriched 10 related papers. Consider them for comparative context: